SuperPulsed 9 Diode Cold Laser as Low as $5,000

Theralase SuperPulsed Therapeutic Laser as low as $5,000
All Theralase Therapeutic Lasers offer:
Features: Superpulsed 905nm technology 5 x 905nm & 4 x 660nm 4 different power levels  Options: Extended warranty available Service loaner program Benefits: Activates all 3 known cellular pathways Able to penetrate 4" into tissue Fast treatment times (<10 minutes total) Eliminates pain Reduces inflammation Accelerates tissue healing
Call 1-866-843-5273 or email sales@theralase.com Discover why Theralase is the safest and most effective therapeutic laser on the market.
www.theralase.com

Theralase Establishes Middle East Distribution Network

Theralase Executes Distribution Agreement with Large Middle East Medical Distributor to Sell Therapeutic Lasers

Toronto, Ontario, Canada – May 30, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that it has entered into an exclusive distribution agreement with Jordan based medical device distributor MediQu to market and sell the Theralase line of therapeutic medical lasers into the Middle East, branded as Theralase Arabia.

Under the terms of the agreement, MediQu will exclusively market and sell the Theralase therapeutic medical laser technology in Jordan, Lebanon, Syria, Iraq, Saudi Arabia, Kuwait, United Arab Emirates, Bahrain, Qatar, Yemen, Oman, Egypt, Sudan, Libya, Algeria, Tunisia, Mauritania and Morocco, in exchange for achievement of certain minimum performance criteria. The current term of the agreement specifies minimum performance criteria of $USD 5 million ramping up over the next 5 years with exclusivity extended into further 5 year terms with annual performance criteria.

Roger Dumoulin-White, President and CEO of Theralase Inc. stated that “MediQu is a large medical device distribution company in the Middle East that has partnered with Theralase to establish Theralase Arabia bringing to the table an impressive array of government, commercial and medical contacts. The Middle East represents a population of 384 million, located in 17 countries with a total GDP of approximately $2.3 trillion and a medical device market that exceeds $5 billion annually according to 2009 statistics. MediQu has established a distribution network that provides sales, marketing and service coverage to customers in 16 of those countries, allowing Theralase Arabia the ability to market, sell and service the Theralase brand of therapeutic medical lasers to this lucrative market. Theralase Arabia expects to exceed USD $5 million annually in the Middle East within 3 to 5 years of launch.”

Roger Dumoulin-White, President & CEO of Theralase went on to say, “Theralase has provided initial training to MediQu’s sales, technical and clinical personnel at our inaugural launch into the region at the 4^th Biennial Emirates Physiotherapy Conference held in Dubai, United Arab Emirates on May 20 and 21, 2012.” He added, “We are currently negotiating with a number of other medical device distributors worldwide who have expressed an interest in marketing, selling and servicing the Theralase brand of superpulsed laser technology in their respective countries.”

Mr. Mohamed ALNabulsi, Project and Sales Manager of MediQu stated, “We were impressed with Theralase’s superpulsed laser system from the beginning and the dominance of the Theralase brand over the other competitive products we investigated. Theralase’s unrivalled scientific and clinical knowledge on the subject of therapeutic lasers was refreshing given the fact that most competitors we spoke to lacked the same understanding of the science. The Theralase technology was the only product on the market that we found that could activate all three known cellular pathways and provide a depth of penetration of four inches into tissue, promoting cellular regeneration at the source of tissue injury.  Initial testing at our key medical facilities in Jordan has been exceptional, with all patients treated experiencing significant pain relief, substantial inflammation reduction and accelerated healing. We are delighted to partner with Theralase to roll-out this technology to the rest of the Middle East countries we service. We have long term relationships with numerous major hospitals, medical clinics and doctors in the region and will be able to proactively promote the Theralase product line immediately. Alternative medicine is embraced in the Middle East and we feel confident that Theralase’s leading edge technology will be accepted and adopted at all levels of government and private medicine.”

About MediQu:

MediQu is the commercial trademark for Fatima for Medical device company servicing 16 countries in the Middle East region. MediQu possesses significant experience regarding sales, service, regional requirements and trade regulations of the various countries in which it does business. In addition, MediQu has built strong connections at the government, commercial and medical levels enabling it to generate strong sale leads, participate in government tenders and clearly communicate the clinical advantage of its products over other competitive products allowing it to dramatically increase market share of its represented products in the region.

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is safe and effective in treating pain, inflammation and for tissue regeneration of neural muscular skeletal conditions and wound healing in both humans and animals. Theralase complies with all FDA, Health Canada, CE and international regulatory approvals to ensure effective, safe and high quality products. Theralase also develops patented Photo Dynamic Compound (PDC) technology focused at targeting and destroying cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         

President and CEO                                                                                                  

416-447-8455 ext. 225                                                                              

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com                                                                         

Greg Bewsh

Director of Investor Relations

416-447-8455 ext. 262

gbewsh@theralase.com  

Arkady Mandel

Chief Scientific Officer

416-447-8455 ext. 242

amandel@theralase.com

Mohamed ALNabulsi

Manager

Theralase Arabia

+962 77777 30004

mnabulsi@theralasearabia.com

www.theralasearabia.com

Theralase to Present at BioFinance 2012 Life Sciences Conference

Toronto, Ontario – May 29, 2012, Theralase Technologies Inc. (TSXV: TLT) announced today that Roger Dumoulin-White, President and CEO will present the latest corporate information at the BioFinance 2012 conference being held in Toronto, Ontario from May 29 to 30, 2012.

BioFinance is a leading life sciences investor conference in Canada which showcases more than 60 diverse life science companies and the investment opportunities that they present. BioFinance 2012 also features 17 investor presentations that are aimed at addressing specific financing and management related issues relevant to life science industries.

Theralase’s presentation will take place Wednesday, May 30th at 3:00 pm in Company Presentation Room 1 at the St. Andrew’s Club and Conference Center. Mr. Roger Dumoulin-White, President and CEO of Theralase will present on the strategic direction and recent accomplishments of the company followed by a short Q&A period and longer one-on-one meeting period.

In other news, Mr. Dumoulin-White was recently interviewed on the TV show “The Next Biggest Winner” which is due to air on Ichannel on Tuesday, June 5^th at 7:30pm.  The Ichannel has over 1.3 million affluent Canadian subscribers who look to its business programming for investment opportunities. For a sneak preview, please visit http://youtu.be/y8VT6Rwp_gY

About Theralase Technologies Inc.:

Theralase Technologies Inc., founded in 1995, designs, develops, manufactures and markets patented, superpulsed laser technology utilized in biostimulation and biodestruction applications. Theralase technology is internationally approved in the safe and effective treatment of pain, inflammation and for the regeneration of tissue in neural muscular skeletal conditions in both humans and animals. Theralase is also researching and developing patented Photo Dynamic Compound (PDC) technology that is focused at targeting and destroying specific cancers, bacteria and viruses when light activated by Theralase’s proprietary and patented laser technologies.

For further information please visit www.theralase.com, regulatory filings may be viewed by visiting www.sedar.com.

This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.

For More Information, please contact:

Roger Dumoulin - White,                                                                         

President & CEO                                                                                       

416-447-8455 ext. 225                                                                              

rwhite@theralase.com

Kristina Hachey

Chief Financial Officer

416-447-8455 ext. 224

khachey@theralase.com

The Science of Laser Therapy and Clinical Applications

The Science of Laser Therapy and  Clinical Applications
Register today for the webinar presentation to learn more about The Science of Laser Therapy and Clinical Applications.   Below are topics that will be covered in the webinar: 1.     How does Laser Therapy work? 2.     Effects of wavelength and power on the therapeutic outcome. 3.     Application and patient benefits. 4.     Return on investment and clinical benefits. Space is limited. Reserve your Webinar seat now at: https://www2.gotomeeting.com/register/435671450     Title: The Science of Laser Therapy and Clinical Applications Date: Thursday, May 24, 2012 Time: 2:00 PM - 3:00 PM EST Regards, The Theralase Team Links www.theralase.com Theralase Laser Clinic Clinic Locator

Laser Therapy in an Injury Rehabilitation Clinic

Tuesday, May 29, 2012 1:00 PM - 2:00 PM EDT

- Show in my Time Zone

Webinar Registration

Below are a few items that will be covered in the Webinar:
Learn how laser can be used by a multidisiplinary rehab team of health providers.
Review common treatments and laser protocols for chronic and acute injuries.
Gain valuable tips on billing for laser through 3rd party payers.

* First Name:

* Last Name:

* Email Address: 

* Address:

* City:

* State/Province:
     Choose one...                                                       Alabama                                 Alaska                                 Arizona                                 Arkansas                                 California                                 Colorado                                 Connecticut                                 Delaware                                 District of Columbia                                 Florida                                 Georgia                                 Hawaii                                 Idaho                                 Illinois                                 Indiana                                 Iowa                                 Kansas                                 Kentucky                                 Louisiana                                 Maine                                 Maryland                                 Massachusetts                                 Michigan                                 Minnesota                                 Mississippi                                 Missouri                                 Montana                                 Nebraska                                 Nevada                                 New Hampshire                                 New Jersey                                 New Mexico                                 New York                                 North Carolina                                 North Dakota                                 Ohio                                 Oklahoma                                 Oregon                                 Pennsylvania                                 Rhode Island                                 South Carolina                                 South Dakota                                 Tennessee                                 Texas                                 Utah                                 Vermont                                 Virginia                                 Washington                                 West Virginia                                 Wisconsin                                 Wyoming                                 Puerto Rico                                 Virgin Islands                                 Guam                                         Alberta                                 British Columbia                                 Manitoba                                 New Brunswick                                 Newfoundland                                 Northwest Territories                                 Nova Scotia                                 Nunavut                                 Ontario                                 Prince Edward Island                                 Quebec                                 Saskatchewan                                 Yukon                         Other     

* Zip/Postal Code:

* Phone:

* Organization:

* Job Title:

---

Webinar organizers are prohibited from soliciting confidential personal information (credit card information, social security numbers, etc.) in the registration form. This questionnaire is not intended to handle sensitive data.

* Are you planning on purchasing a laser? When ?:
  Choose one...  No, I already own a laser.  No, I am not planning on purchasing.  Yes, within 1 month  Yes, within 2-3 months  Yes, within 3-6 months 

* Indicates a required field

By clicking the "Register Now" button you submit your information to the Webinar organizer, who will use it to communicate with you regarding this event and their other services.

 View system requirements